2-[4-(2-amino-ethyl)-phenylamino]-1-phenyl-ethanol | 321708-66-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[4-(2-amino-ethyl)-phenylamino]-1-phenyl-ethanol
• 英文别名: N-(2-phenyl-2-hydroxyethyl)-4-(2-aminoethyl)aniline；2-[4-(2-aminoethyl)anilino]-1-phenylethanol
• CAS: 321708-66-1
• 化学式: C₁₆H₂₀N₂O
• 分子量: 256.348
• InChiKey: YKNYOPMXFOFUOS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  58.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[4-(2-amino-ethyl)-phenylamino]-1-phenyl-ethanol 、 α,α-dihydroxy-4-hydroxy-3-methoxycarbonyl-acetophenone 在 borane dimethyl sulphide complex 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 4-[1-Hydroxy-2-[2-[4-[(2-hydroxy-2-phenylethyl)amino]phenyl]ethylamino]ethyl]-2-(hydroxymethyl)phenol
  参考文献：
  名称：

  A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD

  摘要：

  A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C-2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding Potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.072
• 作为产物：
  描述：

  2-(4-氨基苯)乙胺 在 sodium cyanoborohydride 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 2-[4-(2-amino-ethyl)-phenylamino]-1-phenyl-ethanol
  参考文献：
  名称：

  A multivalent approach to the discovery of long-acting β2-adrenoceptor agonists for the treatment of asthma and COPD

  摘要：

  A multivalent approach was applied to the design of long-acting inhaled beta(2)-adrenoceptor agonists. A series of dimeric arylethanolamines based on the short acting beta(2)-adrenoceptor agonist albuterol were prepared, varying the nature and length of the linker between the basic nitrogens. None of the C-2-symmetric dimers demonstrated increased potency, however dimer 5j, derived from 4-phenethylamine, was found to have increased binding Potency in vitro relative to the parent monomer. Optimization of this structure led to the identification of 22 (milveterol) which demonstrates high potency in vitro and long duration of action in a guinea pig model of bronchoprotection. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.072

文献信息

• Crystalline form of beta2 adrenergic receptor agonist
  申请人：——

  公开号：US20040248985A1

  公开（公告）日：2004-12-09

  The invention provides a novel &bgr; 2 adrenergic receptor agonist in crystalline salt form. The invention also provides pharmaceutical compositions comprising the novel &bgr; 2 adrenergic receptor agonist in crystalline salt form, formulations containing the pharmaceutical compositions, methods of using the crystalline salt to treat diseases associated with &bgr; 2 adrenergic receptor activity, and processes useful for preparing such crystalline compounds.

  该发明提供了一种新型的β2肾上腺素能受体激动剂的结晶盐形式。该发明还提供了包含该新型β2肾上腺素能受体激动剂的结晶盐形式的药物组合物，含有该药物组合物的配方，使用该结晶盐治疗与β2肾上腺素能受体活性相关的疾病的方法，以及用于制备这种结晶化合物的有用过程。
• [EN] CRYSTALLINE beta2 ADRENERGIC RECEPTOR AGONIST<br/>[FR] AGONISTE CRISTALLIN DE RECEPTEUR BETA2-ADRENERGIQUE
  申请人：THERAVANCE INC

  公开号：WO2004011416A1

  公开（公告）日：2004-02-05

  The invention provides a crystalline salt form of a novel β2 adrenergic receptor agonist. The invention also provides pharmaceutical compositions comprising the crystalline form, formulations containing the pharmaceutical compositions, methods of using the crystalline salt form to treat diseases associated with β2 adrenergic receptor activity, and processes useful for preparing such a crystalline compound.

  该发明提供了一种新型β2肾上腺素受体激动剂的结晶盐形式。该发明还提供了包含该结晶形式的药物组合物、含有药物组合物的配方、使用该结晶盐形式治疗与β2肾上腺素受体活性相关疾病的方法，以及用于制备这种结晶化合物的有用过程。
• [EN] CHEMICAL PROCESS AND NEW CRYSTALLINE FORM<br/>[FR] PROCESSUS CHIMIQUE ET NOUVELLE FORME CRISTALLINE
  申请人：GLAXO GROUP LTD

  公开号：WO2005095328A1

  公开（公告）日：2005-10-13

  The present invention relates to the preparation of a ?2 adrenergic agonist in crystalline salt form. In particular the invention relates to preparation of a crystalline salt of compound (I): in particular a crystalline monohydrochloride salt. The invention also relates to a new crystalline form (polymorph) of the monohydrochloride salt of compound (Ia) and a process for preparing it.

  本发明涉及以结晶盐形式制备β2肾上腺素受体激动剂。具体而言，本发明涉及制备化合物(I)的结晶盐，特别是结晶单盐酸盐。该发明还涉及化合物(Ia)的单盐酸盐的新结晶形式（多形态）以及其制备方法。
• [EN] BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY<br/>[FR] DERIVES DE BENZOTHIAZOLE AYANT UNE ACTIVITE D'AGONISTE DU BETA-2-ADRENORECEPTEUR
  申请人：NOVARTIS AG

  公开号：WO2004016601A1

  公开（公告）日：2004-02-26

  Compounds of Formula (I) in free or salt or solvate form, wherein X has the meaning indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the ß2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

  公式(I)中的化合物以自由形式、盐或溶剂形式存在，其中X具有规范中指示的含义，可用于治疗通过激活β2-肾上腺素受体预防或缓解的症状。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。
• [EN] beta 2-ADRENERGIC RECEPTOR AGONISTS<br/>[FR] AGONISTES DES RECEPTEURS ADRENERGIQUES DU BETA 2
  申请人：ADVANCED MEDICINE INC

  公开号：WO2001042193A1

  公开（公告）日：2001-06-14

  Disclosed are multibinding compounds which are β2 adrenergic receptor agonists and are useful in the treatment and prevention of respiratory diseases such as asthma, bronchitis. They are also useful in the treatment of nervous system injury and premature labor.

  本发明涉及多重结合化合物，其为β2肾上腺素能受体激动剂，可用于治疗和预防哮喘、支气管炎等呼吸系统疾病。它们还可用于治疗神经系统损伤和早产。